Every 8-K that Candel Therapeutics, Inc. (CADL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CADL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CADL filings page.
Candel Therapeutics, Inc. (CADL) expanded its Board of Directors from ten to eleven members and appointed Martine Zimmermann, Pharm.D. as a Class III independent director, effective September 8, 2026, with a term expiring at the 2027 annual stockholders’ meeting. Her compensation includes an option to purchase 64,000 shares of common stock, vesting monthly over three years, and a $40,000 annual cash retainer, paid quarterly and pro rated for service. Candel highlights Dr. Zimmermann’s more than 30 years of global regulatory and quality experience as it prepares for a planned Biologics License Application (BLA) submission for aglatimagene besadenovec in the fourth quarter of 2026 and potential commercial readiness. The company also reiterates that more than 1,000 patients have received aglatimagene in clinical trials and summarizes multiple FDA designations, including Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy, for its lead programs.
Candel Therapeutics, Inc. (CADL) furnished an investor presentation outlining clinical, commercial and financial updates across its oncology pipeline. Lead asset aglatimagene besadenovec (CAN-2409) achieved the primary endpoint in a randomized phase 3 trial in intermediate- to high-risk localized prostate cancer, delivering a 30% reduction in risk of disease-free survival events versus placebo plus standard of care (hazard ratio 0.70; P=0.0155) in 745 patients and a 38% reduction in prostate cancer-specific disease-free survival events (hazard ratio 0.62; P=0.0046).
The presentation reports supportive secondary outcomes, including higher pathological complete response rates on 2‑year biopsies (80% vs 63%) and more patients reaching PSA nadir <0.2 ng/mL (67.1% vs 58.6%). In PD‑1–refractory non-small cell lung cancer, phase 2a aglatimagene data show median overall survival up to 25.4 months, compared with historical chemotherapy benchmarks cited in the deck. Second program linoserpaturev (CAN‑3110) in recurrent high‑grade glioma shows median overall survival of about 11–12 months in early studies, versus historical 6–9 months referenced.
Financially, Candel highlights a term loan facility of up to $130 million, a $100 million royalty funding agreement contingent on prostate cancer approval, and $201.6 million of cash and cash equivalents as of June 30, 2026, which it states is expected to fund operations into the first quarter of 2028. The company also notes ongoing pre-commercialization efforts for a potential U.S. launch of aglatimagene in prostate cancer and states that a BLA filing is expected in the fourth quarter of 2026.
Candel Therapeutics reported second-quarter 2026 results and progress across its oncology pipeline. The company is planning a Biologics License Application in Q4 2026 for aglatimagene besadenovec in localized, intermediate- to high-risk prostate cancer, supported by pivotal phase 3 data published in The Lancet Oncology showing improved disease-free survival versus radiotherapy alone. A global pivotal phase 3 AURORA trial in metastatic non-squamous NSCLC has opened enrollment, and development planning continues for linoserpaturev in recurrent glioblastoma.
Research and development expenses rose to $19.8 million from $7.0 million, and general and administrative expenses to $6.9 million from $4.2 million, driving a wider net loss of $38.9 million versus $4.8 million a year earlier, largely due to warrant liability remeasurement. Cash and cash equivalents were $201.6 million at June 30, 2026, up from $119.7 million at December 31, 2025, which the company expects will fund its operating plan into Q1 2028, including preparations for a potential U.S. commercial launch of aglatimagene in 2027 if approved.
Candel Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 23, 2026. As of April 24, 2026, there were 73,270,239 outstanding shares of voting common stock entitled to vote at the meeting.
Stockholders elected four Class II directors to serve until the 2029 annual meeting: Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci. Support ranged from 24,897,348 to 31,591,618 votes "for," with broker non-votes of 22,175,525 for each nominee.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 53,543,020 votes for, 238,508 against, and 87,967 abstentions. No other matters were submitted for a vote.
Candel Therapeutics approved a new employment agreement with Chief Financial Officer Charles Schoch, confirming his at-will role and compensation structure. He will continue to receive an annual base salary of $468,600 and remains eligible for an annual bonus targeted at 40% of base salary, plus standard employee benefits.
If the company terminates him without cause or he resigns for good reason, and he signs a separation agreement, he is entitled to nine months of base salary plus his target annual bonus, paid over nine months, and continued company-paid health insurance contributions for up to nine months, subject to COBRA and other conditions. If such a termination occurs within one month before or 12 months after a change in control, all of his time-based equity awards will fully vest. The agreement also includes customary confidentiality, non-competition and non-solicitation provisions.
Candel Therapeutics reported extended follow-up results from its pivotal phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer. In 745 patients, adding aglatimagene to standard radiotherapy improved prostate cancer–specific disease-free survival by 39% versus placebo (hazard ratio 0.61; 95% CI 0.44–0.85; p=0.0031) after a median 58‑month follow-up.
In the 635‑patient intermediate‑risk subgroup, prostate cancer–specific disease-free survival improved by 41% (hazard ratio 0.59; 95% CI 0.41–0.84; p=0.0034). Trends favored aglatimagene for time to biochemical failure, time to metastasis, and time to new anticancer therapy, with very low metastatic rates in the intermediate‑risk arm.
The regimen was generally well tolerated, with mostly mild to moderate, short‑lived systemic symptoms and similar rates of serious adverse events and treatment discontinuations versus placebo. Candel plans to submit a Biologics License Application for CAN‑2409 in localized prostate cancer in the fourth quarter of 2026.
Candel Therapeutics reported a first quarter 2026 net loss of $8.9 million, reversing from net income of $7.4 million a year earlier, mainly due to higher operating expenses and a smaller gain from warrant revaluation. Research and development expenses rose to $9.8 million from $4.0 million, and general and administrative expenses increased to $6.4 million from $4.1 million, reflecting clinical, manufacturing, and commercial readiness spending for aglatimagene.
Candel strengthened its balance sheet, with cash and cash equivalents rising to $194.8 million as of March 31, 2026 from $119.7 million at year-end, helped by issuing 18.3 million shares for roughly $100 million in gross proceeds and a separate $100 million royalty funding agreement. The company expects this cash to fund operations into Q1 2028.
Strategically, Candel plans to submit a Biologics License Application for aglatimagene in localized, intermediate- to high-risk prostate cancer in Q4 2026, initiate a pivotal phase 3 trial in metastatic non-small cell lung cancer in June 2026, and has secured a U.S. commercialization partnership with EVERSANA to support a potential launch.
Candel Therapeutics reported fourth quarter and full year 2025 results and outlined key clinical and financing milestones. Research and development expenses rose to $30.5M in 2025 from $19.3M in 2024, while general and administrative expenses increased to $17.8M from $14.1M. Net loss narrowed to $38.2M in 2025 from $55.2M in 2024, helped by $10.1M of net other income, mainly from warrant liability revaluation. Cash and cash equivalents were $119.7M as of December 31, 2025, compared with $102.7M a year earlier.
The company completed a February 2026 follow-on equity offering that generated $93.5M in net proceeds and entered a $130M term loan facility, drawing $50M at closing. Based on these resources, Candel expects to fund its operating plan into Q1 2028. The plan includes a planned pivotal phase 3 trial of aglatimagene besadenovec in non-small cell lung cancer, a planned BLA submission for aglatimagene in localized intermediate- to high-risk prostate cancer in Q4 2026, and continued development of linoserpaturev in recurrent high-grade glioma.
Candel Therapeutics entered into an underwriting agreement for a public stock offering of 18,348,624 common shares at $5.45 per share, for expected gross proceeds of $100 million. Underwriters also have a 30‑day option to buy up to 2,752,293 additional shares.
Candel estimates net proceeds of about $93.5 million, or $107.6 million if the option is fully exercised. The company plans to use the cash to prepare for the launch and commercialization of CAN‑2409 in early localized prostate cancer, continue the phase 3 trial of CAN‑2409 in non‑small cell lung cancer, and for general corporate purposes. Based on the expected proceeds from the base deal, Candel believes its cash and cash equivalents will fund operations into the first quarter of 2028.
Candel Therapeutics entered a royalty-based funding agreement with funds managed by RTW Investments tied to its lead therapy aglatimagene besadenovec (CAN-2409) for intermediate- and high-risk localized prostate cancer. RTW will pay $100 million to Candel if the therapy receives U.S. FDA approval, providing non-dilutive capital for a potential U.S. commercial launch.
In return, RTW will receive a tiered royalty on U.S. net sales: 4.67% on annual sales up to $1 billion and 1.33% on sales above that level, with a ratchet mechanism that can raise the lower tier to 6.67% if sales fall below specified thresholds. Royalty payments start after the first U.S. commercial sale and stop once RTW has received $250 million in total royalties, and the agreement includes a buy-out option for change-of-control or product sale scenarios.
Candel also reported preliminary, unaudited cash and cash equivalents of approximately $119.7 million as of December 31, 2025, which, combined with the potential RTW funding, would support commercialization and further development if aglatimagene is approved.
Candel Therapeutics reported that it will host a virtual Research and Development Day on December 5, 2025, from 11:00 a.m. to 1:45 p.m. Eastern Time. The event will provide an extensive overview of the company’s viral immunotherapy approach and its oncology-focused pipeline.
The investor presentation used for the event is being furnished as Exhibit 99.1 and will also be available in the investor relations section of the company’s website. Candel states that this information is being furnished rather than filed and will not be treated as part of its other securities law filings.
Candel Therapeutics, Inc. filed a current report to disclose that it announced its financial results for the quarter ended September 30, 2025. The company issued a press release on November 13, 2025, and that release is included as Exhibit 99.1 to the report.
The disclosure is furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Candel Therapeutics by its President and Chief Executive Officer, Paul Peter Tak, M.D., Ph.D., FMedSci.
Candel Therapeutics entered a Loan and Security Agreement for up to $130.0 million in term debt with Trinity Capital and other lenders, securing the debt with a first‑priority lien on substantially all assets. The Company drew the $50.0 million first tranche at closing. Additional tranches of $20.0 million, $30.0 million, and $30.0 million are available upon meeting specified milestones or lender discretion.
The facility matures on October 1, 2030, carries a floating rate with a 9.75% floor (initial rate 10.25%), a 36‑month interest‑only period extendable by 12 months upon a commercial milestone, an Exit Fee of 4.25% on amounts drawn at maturity/early termination, and tiered prepayment premiums of 3%/2%/1%. If market cap is below $550 million, minimum pledged cash covenants apply at 67.5% of outstanding obligations from July 1, 2026 (until specified financings) and 75% from the earlier of October 1, 2027 or certain regulatory notices until approvals.
Lenders received warrants equal to 3.0% of each draw at a $5.89 exercise price; the first draw produced a warrant for 254,642 shares (10‑year term, cashless exercise). Existing warrants’ expiration was extended to September 30, 2027, and certain holders agreed to a 6‑month lock‑up and provided releases. Cash and equivalents were $87.2 million as of September 30, 2025. Interim CAN‑3110 data showed mOS of 11.8 months (arm A) and 12.0 months (arm B); additional arm C data are expected in Q4 2026.
Candel Therapeutics, Inc. reported that on August 18, 2025 it signed a First Amendment to its lease with 117 Kendrick DE, LLC for approximately 15,197 rentable square feet at 117 Kendrick Street in Needham, Massachusetts. The amendment extends the lease term from August 31, 2026 to August 31, 2029. Starting September 1, 2026, annual base rent will be $607,880 and will rise by $15,197 each year during the extended term. The full lease amendment is filed as an exhibit and certain confidential portions have been redacted.
Candel Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended June 30, 2025. The company reported these quarterly results through a press release dated August 14, 2025, which is attached as Exhibit 99.1 to this Form 8-K.
The information about these results, including the press release, is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Candel Therapeutics by President and Chief Executive Officer Paul Peter Tak, M.D., Ph.D., FMedSci.
Candel Therapeutics has announced a registered direct offering of 3,221,395 shares of common stock at $4.67 per share, expected to raise approximately $15.0 million in gross proceeds. The offering price equals the closing price reported on Nasdaq Global Market on June 23, 2025.
Key details of the offering include:
- Purchasers include existing healthcare-focused institutional investors, executive officers, and directors
- Offering is made under shelf registration statement (File No. 333-266605) declared effective August 12, 2022
- Closing anticipated for June 25, 2025, subject to customary conditions
The company, an emerging growth company, is conducting this offering to strengthen its financial position. The securities purchase agreement was signed on June 23, 2025, with shares being offered through a registered direct offering structure. This strategic financing move involves both institutional and insider participation, potentially signaling management's confidence in the company's prospects.